Abstract
During the period from May, 1995 to August, 1996, three patients with Stage III or IVa invasive thymoma received chemotherapy consisting of cisplatin, doxorubicin and methylprednisolone (1000 mg on days 1 through 5, and 500 mg on days 6 and 7). The first case, a 55-year-old woman, who underwent extended thymectomy 7 years ago, was found to have a recurrent tumor in the left pleural cavity. The second case, a 38-year-old man, who had first operation 3 years ago, developed recurrent tumor in the right pleural cavity. These two patients were treated with the above regimen as the primary mode of therapy. The third case, a 61-year-old woman, had a thymoma with direct invasion to right upper lobe. The same chemothrapy regimen was employed as the induction chemotherapy. All patients show3ed a major response to treatment with only a small amount of tumor remaining. The effectiveness of chemotherapy in the treatment of malignant tumors has been recently reported to be at least partly due to induction of apoptosis. Steroids are known to induce apoptosis in normal thymic cells, and thus steroid in chemotherapy regimen against invasive thymoma may enhance the effect of anti-cancer drugs through the induction of apoptosis.
Similar content being viewed by others
References
Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485–2492, 1981
Haussen SR, Nibbelink D, Hackett E, Vick NA, Cape CA: Effect of adrenocorticosteroid therapy of myasthenia gravis on associated malignant thymomas. Neurology 25: 347, 1975
Hu E, Levine J: Chemotherapy of malignant thymoma. Case report and review of the literature. Cancer 57: 1101–1104, 1986
17: 2019–2024, 1990
Loehner PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R: Cisplatin plus doxorubicine plus cyclophosphamide in metastatic or recurrent thymoma. Final results of an intergroup trial. J Clin Oncol 12: 1164–1168, 1994
Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, Rea F: Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68: 30–33, 1991
Green D, Forman H: Response of thymoma to steroids. Chest 65: 114–116, 1974
Lows SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967, 1993
Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55: 2122–2128, 1995
Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O’Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to Cisplatin and pentoxifylline. Cancer Res 55: 1649–1654, 1995
Iwata M, Iseki R, Sato K, Tozawa Y, Ohoka Y: Involvement of protein kinase C-ε in glucocorticoid-induced apoptosis in thymocytes. Int Immunol 6: 431–438, 1994
Nakahara K, Ohno K, Hashimoto J, Maeda H, Miyoshi S, Sakurai M, Monden Y, Kawashima Y: Thymoma. Results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg 95: 1041–1047, 1988
46: 26–30, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suda, T., Sugimura, S., Hattori, Y. et al. High-dose methylprednisolone-containing chemotherapy in advanced invasive thymoma —Report of three cases—. Jpn J Thorac Caridovasc Surg 46, 115–120 (1998). https://doi.org/10.1007/BF03217734
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03217734